Articles dans des revues avec comité de lecture (158)
99.
Roumeguere, T., Zouaoui Boudjeltia, K., Hauzeur, C., Schulman, C., Vanhaeverbeek, M., & Wespes, E. (2009). Is there a rationale for the chronic use of phosphodiesterase-5 inhibitors for lower urinary tract symptoms secondary to benign prostatic hyperplasia? BJU international, 104(4), 511-517. doi:10.1111/j.1464-410X.2009.08418.x102.
Goris, M., Roumeguere, T., Addla, S. K., Schulman, C., & Djavan, B. (2009). Phytotherapy in Chronic Prostatitis. Current prostate reports, 7, 39-43. doi:10.1007/s11918-009-0007-9103.
Perimenis, P., Roumeguere, T., Heidler, H., Roos, E., Belger, M., & Schmitt, H. (2009). Evaluation of patient expectations and treatment satisfaction after 1-year tadalafil therapy for erectile dysfunction: the DETECT study. Journal of Sexual Medicine, 6(1), 257-267. doi:10.1111/j.1743-6109.2008.01027.x106.
Roumeguere, T., Zouaoui Boudjeltia, K., Hauzeur, C., Ramal, A., Schulman, C., Vanhaeverbeek, M., Ducobu, J., & Wespes, E. (2008). Diminution du rapport ApoB/ApoA-1 et amélioration du risque cardiovasculaire : effet pleïotropique du tadalafil ? Étude préliminaire sur volontaires sains. Progrès en urologie, 18(13), 1087-1091. doi:10.1016/j.purol.2008.09.057108.
Roumeguere, T., Verheyden, B., Arver, S., Bitton, A., Belger, M., & Schmitt, H. (2008). Therapeutic response after first month of tadalafil treatment predicts 12 months treatment continuation in patients with erectile dysfunction: results from the DETECT study. Journal of Sexual Medicine, 5(7), 1708-1719. doi:10.1111/j.1743-6109.2008.00790.x109.
Lemy, A., Wissing, K. M., Rorive, S., Zlotta, A., Roumeguere, T., Muniz Martinez, M. C., Decaestecker, C., Salmon, I., Abramowicz, D., Vanherweghem, J.-L., & Nortier, J. (2008). Late onset of bladder urothelial carcinoma after kidney transplantation for end-stage aristolochic acid nephropathy: a case series with 15-year follow-up. American journal of kidney diseases, 51(3), 471-477. doi:10.1053/j.ajkd.2007.11.015